Sustained Efficacy and Safety of Ibrutinib in Relapsed/Refractory CLL
At a follow-up of almost 4 years, over two-thirds of patients randomly assigned to receive ofatumumab crossed over to receive ibrutinib.
Chronic Lymphocytic Leukemia News
CHRONIC LYMPHOCYTIC LEUKEMIA ADVISOR
Chronic Lymphocytic Leukemia News
Disease Progression Is Associated With Increased Costs for Patients With Hematologic Malignancies
Relative increases in health care costs associated with disease progression were more than 30% in subgroups of patients with CLL and NHL.
Designing a Clinical Trial to Evaluate Multistage Treatment Approaches in CLL
Sequential multiple assignment randomized trials (SMART) have an adaptive design based on patient response to therapy.
Ibrutinib Plus Nivolumab in 4 Cohorts of Patients With R/R NHL or CLL
According to results of an exploratory study, patients with Richter transformation may benefit from treatment with ibrutinib plus nivolumab.
Fixed Duration of Venetoclax-Rituximab for CLL May Prolong Survival
When used as a fixed-duration venetoclax-rituximab combination, 62% of patients achieved an undetectable minimal residual disease level in peripheral blood.
Gly101Val Mutation Directly Causes Resistance to Venetoclax
Researchers identified a single heterozygous nucleotide variant that confers resistance to venetoclax, and it’s a mutation that may be detected years before clinical relapse occurs.
Ibrutinib + Rituximab Reportedly Superior to Current Standard of Care in Younger Patients With CLL
Three-year outcomes reveal a new standard of care in patients with CLL who are younger than 70.
New Standard of Care in CLL Proposed for Older Patients
Although PFS with ibrutinib-containing regimens was favorable compared with bendamustine rituximab, overall survival was not different across the study arms.
CAR-T and Ibrutinib: Better Together?
Although CAR-T alone has shown utility in CLL, evidence suggests the addition of ibrutinib could improve the durability of remission.
Liso-Cel Highly Active in Relapsed/Refractory Chronic Lymphocytic Leukemia
Favorable data on liso-cel bolsters its chances of moving into further stages of development, provided complete responses remain durable.
Siglec-6 Identified as Drug Target for Chronic Lymphocytic Leukemia
Cell surface antigen Siglec-6 was broadly expressed in chronic lymphocytic leukemia after transplantation, suggesting a new potential drug target.
Prognostic and Therapeutic Significance of TP53 Alterations in CLL
There are several novel agents, such as ibrutinib, idelalisib, and venetoclax, that could improve outcomes in CLL patients with 17p deletions and TP53 mutations.
Activation-Induced Cytidine Deaminase Transcripts Linked to More Aggressive CLL
AID is a mutator enzyme that plays an essential role for somatic hypermutation and class switch recombination during effective adaptive immune responses.
Novel Regimen for High-Risk CLL Patients Seeking Transplantation
A regimen showed favorable minimal residual disease negativity in patients with high-risk CLL, allowing many to pursue transplantation.
Lenalidomide Induces Immunity, Produces Clinical Response in CLL
Immune changes in the tumor microenvironment were associated with clinical response to lenalidomide in patients with chronic lymphocytic leukemia.
Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment
High comorbidity burden was associated with worse survival outcomes in patients with chronic lymphocytic leukemia who were treated with ibrutinib.
Duvelisib Delayed Progression in CLL/SLL: Study
Duvelisib improved PFS by more than 3 months compared with ofatumumab, the current standard of care, in relapsed or refractory CLL and SLL.
Pilot Study Supports Lower Dose of Ibrutinib in Chronic Lymphocytic Leukemia
In patients with chronic lymphocytic leukemia, a lower ibrutinib dose appears to confer sufficient biological activity, but further study is needed.
Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
Investigators found that dosing of IgRT in CLL at target levels higher than conventional parameters may offer a therapeutic benefit.
Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
Transplant-naive patients were more likely to achieve an optimal drug response — but were also more prone to severe cytokine release syndrome and neurotoxicity.
Want to read more?
Please login or register first to view this content.
Next post in Chronic Lymphocytic Leukemia
